NPP General Secretary Confident of Election Victory, Calls for Vigilance as Polls CloseSyriaâs besieged Assad makes overtures to US in bid to surviveAmong the many countries Michael Kim flew to in the 2024 PGA Tour season was Mexico for the World Wide Technology Championship. Orlando Ramirez/Getty Images The life of a PGA Tour pro can seem glamorous, darting across the globe and back all year long chasing giant purses. But to accomplish all that jetting around, pro golfers rely on, well, jets. And all that airline travel, plus the hotel stays once they arrive, comes at a shocking cost. We know that thanks to Tour pro Michael Kim . Kim has become one of the best follows on social media for golfers. He regularly dispenses valuable and interesting insight into the behind-the-scenes life of a PGA Tour pro , both the good and the bad. Itâs the kind of transparency modern sports fans love to see, and Kim provided his latest dose this week to his followers on X. In a post on Friday morning, Kim shared a screenshot of a graph showing the total money he spent on flights and hotels for PGA Tour events in the 2024 season, revealing a staggering sum: $92,698.11 . That enormous cost accumulated while Kim played in 30 different PGA Tour events in 2024, including stops in Hawaii, Mexico, Canada, Puerto Rico, the Dominican Republic, Bermuda and points all across the continental U.S. Kim added that the $92K+ total he spent featured âzero dollars spent on private flights, and rarely business class.â Unlike some Tour stars, Kim always flies commercial, presumably making his travel costs far lower than others, as he noted in his post. âCanât imagine some of the top guysâ costs,â Kim wrote. đ
This is my spending on flights and hotels for 30 tournaments in 2024. Zero dollars spent on private flights, and rarely business class. Canât imagine some of the top guysâ costs... At least Iâm racking up some CC points! pic.twitter.com/tnqLHRl2fF Kimâs example is helpful to educate golf fans on how costly it can be to be a pro golfer outside of the elite ranks. You have to spend big to have any chance of making a living, and little money is guaranteed. Kim, who has one career Tour victory, still ended up in the green for the 2024 season. Despite missing 13 cuts and only capturing two top-10 finishes, Kimâs official money for the season came out to $1,484,233 . The lionâs share of those earnings, though, came from just five tournaments, further showing the financial insecurity many players on the lower rungs of the Tour face. Ironically, his biggest paycheck of the season was $310,800 for a T6-finish at the American Express, which was just his second start of the year and was played in California, the state where he grew up. Latest In News Golf.com Editor As managing producer for GOLF.com, Cunningham edits, writes and publishes stories on GOLF.com, and manages the brandâs e-newsletters, which reach more than 1.4 million subscribers each month. A former two-time intern, he also helps keep GOLF.com humming outside the news-breaking stories and service content provided by our reporters and writers, and works with the tech team in the development of new products and innovative ways to deliver an engaging site to our audience.
b777-800
ă
None
Column: Money wasted on culturally divisive issues could be spent helping kidsâMiracleâ mother who survived traumatic birth meets crucial blood donor team
With technical prowess and considerable style, Marta danced around two sliding defenders, outwitted a goalkeeper and calmly scored as another player rushed forward in desperation to stop her. It was more Marta Magic.
Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ÂŽ (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ÂŽ ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ÂŽ (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ÂŽ ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ÂŽ molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ÂŽ immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ÂŽ IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ÂŽ is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ÂŽ (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ÂŽ full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ÂŽ ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ÂŽ Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ÂŽ , and it is also part of the Nasdaq-100 Index ÂŽ , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ÂŽ (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE Amgen
Much was made about Michigan's attempted flag planting after its 13-10 win over Ohio State in Columbus in Week 14. Players from both teams met in an altercation at midfield, resulting in the use of pepper spray by the police, and the Big Ten fined each school $100,000 for their role in the incident. That seemed like the end of it, until Wolverines coach Sherrone Moore was shown on the jumbotron at the Michigan men's basketball game against Iowa on Saturday. Moore took one last opportunity to needle Ohio State. In the first half, the game ops team at Crisler Arena pointed the camera at Moore, and he did the rest. Moore fired up the crowd before pretending to plant a flag. Sherrone Moore hypes up the faithful Michigan crowd and emphatically plants an imaginary flag. The crowd liked it, to say the least. pic.twitter.com/xbakn2pxsn Moore addressed the flag-planting fracas immediately after the game last weekend, saying emotions got the best of both sides. He also admitted Michigan could have handled the situation differently. "Our guys, I did see they had the flag," Moore said. "Guys were waving it around, and their guys charged us. There was emotion on both sides, and it can't happen. Rivalry games get heated, especially this one. This is the biggest one in the country. We gotta handle that better." Clearly, Moore wasn't quite ready to put the win or the beef to bed just yet. That was probably a good thing for the Michigan basketball team, which needed every bit of energy the Crisler Center had to offer. The Wolverines pulled out an 85-83 win over the Hawkeyes thanks to Roddy Gayle Jr.'s game-winning bucket with just three seconds left.Baltimore Ravens quarterback Lamar Jackson kept the overall lead in fan voting numbers revealed Monday for the NFL Pro Bowl Games with Philadelphia running back Saquon Barkley a close second. Jackson topped vote-getters with 82,402 and Barkley was next, only 320 votes behind. Barkley was 4,079 votes back of Jackson in last week's first voting results. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.J&K Got Rs 69.58 Lakh For Development Of Wildlife Habitats In 2023-24
Amazon is selling a $130 portable space heater for just $49, and shoppers say it 'works great'With Syrian rebels edging ever-closer to the capital, President Bashar Assad is making a last-ditch attempt to remain in power, including indirect diplomatic overtures to the U.S. and President-elect Donald Trump, according to people with direct knowledge of the situation. Assad is ordering his army to fall back to defend Damascus, essentially ceding much of the country to insurgents, who seized the major cities of Aleppo and Hama in a lightning offensive over the past week. Theyâre now on the outskirts of Homs, less than 100 miles (160 kilometers) to the north. As his remaining troops dig in, Syriaâs longtime ruler is signaling his willingness to reach a deal that would allow him to hold on to the rump territory his army controls, or guarantee his safe passage into exile if needed, said the people. They spoke on condition of anonymity to discuss secret meetings. One offer Assad made to the U.S. via the United Arab Emirates is for Syria to cut all involvement with Iran-backed militant groups, such as Hezbollah, if Western powers wield influence to stem the fighting, the people said. Another initiative saw Assad dispatch a senior Christian leader to meet Hungarian President Viktor Orban to relay what he sees as an existential threat to Syriaâs Christian minority if Islamist rebels prevail, according to other people familiar with the plan. The intention was that Orban, a Trump ally, would convey this danger to the incoming U.S. president, they said. Itâs a dramatic turn of events for a dynasty thatâs ruled Syria with an iron fist for half a century, crushed peaceful protests in 2011 and clung to power through years of civil war that spurred one of the worst humanitarian crises of modern times. Iranian and Russian military support was crucial to the survival of the 59-year-old president, but both are now distracted and stretched thin by other conflicts. âAssad is in huge danger â itâs almost like in 2015 when the insurgents were at the gates of Damascus,â said Sergei Markov, a political consultant close to the Kremlin, referring to the year Russia intervened to save him. Western nations were equally surprised, including the U.S., which had largely relinquished much of its influence in Syria to Iran, Russia and Turkey but has reacted to protect its interests, according to senior officials. Multiple Western officials said it was difficult to see Assad remaining in power. The fall of Homs, Syriaâs third-largest city, could cut the highway linking Damascus and the countryâs west and Mediterranean coast â the stronghold of the Assads and loyalists from their Alawite sect. The presidentâs whereabouts are unclear, although heâs believed to be in Damascus or his hometown of Qardaha, close to Russiaâs Khmeimim air base. Itâs also possible heâs in the Iranian capital, Tehran, a person familiar with U.S. policy said Saturday. Assadâs office issued a statement condemning ârumors and fake news,â saying the the president remains in the capital. Assad has ordered the bulk of Syriaâs remaining army â estimated at between 30,000 to 40,000 fighters â to rush to defend Damascus, according to two people familiar with the matter. An army spokesman said in a TV address on Saturday that it was strengthening its defenses around the city and in southern Syria. The main rebel offensive has been led by Hayat Tahrir al-Sham, or HTS, a former al-Qaida affiliate, and various armed groups backed by Turkey. Other fighters have joined in, including army defectors whoâd fought the regime and laid down arms in previous ceasefires, said the people. As rebels converge on Damascus from the north and south, Iran had drawn back its presence in Syria, leaving its military advisers concentrated around the capital, according to the people. Some Tehran-backed Iraqi militia have also returned their country after the government ceded the eastern city of Deir Ezzor to U.S.-backed Kurdish fighters, they said. Russian personnel now remain mainly around the capital and at the Khmeimim air base and Tartous naval base, they said. After a meeting with his Iranian and Turkish counterparts in Doha on Saturday, Russian Foreign Minister Sergei Lavrov said Moscow is âtrying to do everything not to allow terrorists to prevail.â âWe donât want them to follow the fate of Iraqis, Libyans and other nations who were disturbed by the people desiring to keep their domination,â he said. Trump said Saturday a withdrawal from Syria might âbe the best thing that can happenâ to Russia and that troops shouldnât get involved in the fighting. Back channels Russia has launched airstrikes around Homs to try and stall the rebel advance. But with signs the Kremlinâs help may not be enough, Assad is pressing on with back-channel negotiations. A key goal would be retaining control of a portion of the country and addressing Turkeyâs demands for a political transition and the potential return of millions of Syrian refugees, a major issue for Ankara. Assad is also proposing a new constitution and talks with the mostly exiled political opposition, according to the people familiar with the outreach. Itâs unclear if the efforts will bear fruit. Events on the battlefield have their own momentum, and even countries such as Turkey that have influence over the rebels may not be able to fully control events. âI donât think any of these outside powers have the leverage over their proxies to change the course of what is happening on the ground,â said Andreas Krieg, director of London-based MENA Analytica Ltd. âAt this moment most bets are that the Assad regime may not be able to hold out.â Patriarch visit It was against that backdrop that Assad sent Syriac Orthodox Patriarch Ignatius Aphrem II to Hungary on Monday to relay his fears. Syriaâs Christian community makes up about 10% of the countryâs 24 million population. The plan to have Orban relate this message to Trump was described by an aide to the patriarch and another person with knowledge of the encounter. People close to Trump couldnât immediately comment, but said he had dispatched his in-law and Middle East adviser, Massad Boulos, to the UAE on Saturday to discuss the situation in the region. Assad has pursued similar tactics before. HTS leader Abu Mohammad al-Golani and other rebels have in recent days attempted to allay the fears of Christians and Syriaâs other minorities that they envision a form of Islamic rule. Assadâs own Alawite community, which has stuck by him since 2011 and paid a heavy price to defend the regime, also appears to sense the end may be near. Nariman, an Alawite woman reached by phone in Damascus on Friday said she, her husband whoâs in the security forces and their 23-year-old son were fleeing to their ancestral village near Jableh in western Syria. She said there were many families like hers. Nobody is going to fight for Assad this time, she said, asking not to be identified by her last name for reasons of safety. Š2024 Bloomberg L.P. Visit bloomberg.com. Distributed by Tribune Content Agency, LLC.
December 9, 2024 This article has been reviewed according to Science X's editorial process and policies . Editors have highlightedthe following attributes while ensuring the content's credibility: fact-checked peer-reviewed publication trusted source proofread by Vienna University of Technology About 100 years ago, humanity learned to see with the help of electrons. In 1924, Louis de Broglie posited thatâlike light particlesâelectrons have wave properties. In 1927, the U.S. physicists Davisson and Germer provided experimental proof of this. A few years later, the engineers Ernst Ruska and Max Knoll built the first electron microscope, which was more powerful than any light microscope . Given that electron waves are diffracted by much smaller objects than photons, the optical resolution limit of light was surmounted, heralding a new era of microscopy. Combining two worlds: Quantum electron microscopy "Electron microscopy is a crazy, cool technique," Philipp Haslinger, Associate Professor at the TU Wien, says. "In principle, we could use it to look at the spike proteins of a virus or its DNAâat the level of atoms, the pixels of reality." Haslinger, a quantum optics specialist, deliberately says "could," because there is a catch: The electrons are typically so high in energy that they destroy sensitive samples. For this reason, biological processes cannot be observed "live" with electron microscopes. According to Haslinger, there is one possible solution: "Gaining more information from fewer electrons." In pursuit of this goal, his 11 member team uses "quantum electron microscopy," which combines classic electron microscopy with the newer world of photon -based quantum optics. Spooky imaging One of their possible ideas is based on a method going by the evocative name of "quantum ghost imaging" or Zou-Wang-Mandel effect . In this method, an entangled electronâphoton pair generates the image of the object. This is how it works: first, an electron races through a translucent medium and "overtakes" the light there, "a bit like an airplane going supersonic," explains Haslinger. This creates a photon, which is taken to be entangled with the electron. While the electron travels towards the sample, the photon enters a camera detector. As the two are entangled, the photon can be used to measure whether the electron has hit the sample. If the detected photons can be space-resolved successfully, the image of the object can be constructed. At least, this is the theory behind the approach published in Quantum Science and Technology . "Several research groups around the world are working on establishing the first proof of this entanglementâand we are up in the front line," says Haslinger. In practice, the innovative ideas are fraught with technical challenges. The team first had to adjust the existing microscope. "Normally, electron microscopes are built completely sealed from lightâbut we drill holes in them so that photons can escape so as to be measured," says the physicist. Promising outlook for biology and materials science What is needed now is proof of principle that the method can generate electronâphoton pairs. "In fact, it could happen any day now," hopes Haslinger. "We have already recorded a ghost image. So we were able to see with electrons what the photon 'saw.' Now we are looking for evidence of interference phenomena between the two particles. Finding this evidence would give us clear smoking-gun proof of entanglement." An established variant of ghost imaging that uses entangled photonâphoton pairs has proven its worth when observing particularly light-sensitive objects. If Haslinger's plan works out, this sparing treatment of the sample could for the first time be combined with the high optical resolution of electrons. Such a development would open up promising applications, for example, in battery research: The molecular and atomic changes on the surfaces of materials during charging and discharging could be better observed and this would help to identify optimized materials. There might also be spectacular new insights in biology, such as observing proteins as they fold without their being broken during irradiation. "Watching life as it happens, that would be a dream," beams Haslinger. A good 20 years ago, as a young physics student, he attended lectures by Anton Zeilinger, who got him interested in quantum optics. Now he and his colleagues could bring a new quality to electron microscopy, the history of which began a century ago. More information: Philipp Haslinger et al, Spin resonance spectroscopy with an electron microscope, Quantum Science and Technology (2024). DOI: 10.1088/2058-9565/ad52bc Journal information: Quantum Science and Technology Provided by Vienna University of Technology
When Katja Vogt considers a Jaguar, she pictures a British-made car purring confidently along the Italian coastline â a vision of familiarity that conveys "that dreaming, longing feeling we all love." She's not sure what to think about Jaguar now after the 89-year-old company announced a radical rebranding that featured loud colors and androgynous people â but no cars. Jaguar, the company says, will now be JaGUar. It will produce only electric vehicles beginning in 2026. Bad attention is good attention, Jaguar execs would appear to believe. The car brand has prompted mockery online for posting a glitzy ad without a single car in it. Jaguar Say goodbye to British racing green, Cotswold Blue and black. Its colors are henceforth electric pink, red and yellow, according to a video that sparked backlash online. Its mission statement: "Create exuberance. Live vivid. Delete ordinary. Break moulds." "Intrigued?" @Jaguar posted on social media. People are also reading... "Weird and unsettled" is more like it, Vogt wrote on Instagram. "Especially now, with the world feeling so dystopian," the Cyprus-based brand designer wrote, "a heritage brand like Jaguar should be conveying feelings of safety, stability, and maybe a hint of rebellion â the kind that shakes things up in a good way, not in a way that unsettles." After 155 years, the Campbell Soup company is changing its name Our brands, ourselves Jaguar was one of several iconic companies that announced significant rebrandings in recent weeks, upending a series of commercial â and cultural â landmarks by which many modern human beings sort one another, carve out identities and recognize the world around them. Campbell's, the 155-year-old American icon that artist Andy Warhol immortalized in pop culture decades ago, is ready for a new, soupless name. Comcast's corporate reorganization means there will soon be two television networks with "NBC" in their name â CNBC and MSNBC â that will no longer have any corporate connection to NBC News, a U.S. legacy news outlet. CNBC Richard Drew, Associated Press One could even argue the United States itself is rebranding with the election of former President Donald Trump and Republican majorities in the House and Senate. Unlike Trump's first election in 2016, he won the popular vote in what many called a national referendum on American identity. Are we, then, the sum total of our consumer decisions â what we buy, where we travel and whom we elect? Listen now and subscribe: Apple Podcasts | Google Podcasts | Spotify | Stitcher | RSS Feed | SoundStack | All Of Our Podcasts Certainly, it's a question for those privileged enough to be able to afford such choices. Volumes of research in the art and science of branding â from "brandr," an old Norse word for burning symbols into the hides of livestock â say those factors do contribute to the modern sense of identity. So rebranding, especially of heritage names, can be a deeply felt affront to consumers. "It can feel like the brand is turning its back on everything that it stood for â and therefore it feels like it's turning its back on us, the people who subscribe to that idea or ideology," said Ali Marmaduke, strategy director with the Amsterdam-based Brand Potential. He said cultural tension â polarization â is surging over politics, wars in Russia and the Mideast, the environment, public health and more, creating what Marmaduke said is known as a "polycrisis": the idea that there are several massive crises converging that feel scary and complex. Campbell's soups Ross D. Franklin, Associated Press "People are understandably freaked out by that," he said. "So we are looking for something that will help us navigate this changing, threatening world that we face." Trump's "Make America Great Again" qualifies. So did President Joe Biden's "Build Back Better" slogan. Campbell's soup itself â "Mmm Mmm Good" â isn't going anywhere, CEO Mark Clouse said. The company's new name, Campbell's Co., will reflect "the full breadth of our portfolio," which includes brands like Prego pasta sauce and Goldfish crackers. What is Jaguar? None of the recent activity around heritage brands sparked a backlash as ferocious as Jaguar's. The company stood as a pillar of tradition-loving British identity since World War II. The famous "leaper" cat Jaguar logo is pictured in 2019 at the Auto show in Paris, France. Christophe Ena, Associated Press Jaguar said its approach to the rebrand was rooted in the philosophy of its founder, Sir William Lyons, to "copy nothing." What it's calling "the new Jaguar" will overhaul everything from the font of its name to the positioning of it's famous "leaper" cat. "Exuberant modernism" will "define all aspects of the new Jaguar world," according to the news release. The approach is thought to be aimed at selling fewer cars at a six-figure price point to a more diverse customer base. The reaction ranged from bewilderment to hostility. Memes sprouted up likening the video to the Teletubbies, a Benetton ad and â perhaps predictably â a bow to "woke" culture as the blowback intersected with politics. Hereâs what the Pizza Hut of the future looks like Tropicana fans are ditching the brand after a orange juice bottle redesign The business news you needJoin our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More With 77% of enterprises already victimized by adversarial AI attacks and eCrime actors achieving a record breakout time of just 2 minutes and 7 seconds , the question isnât if your Security Operations Center (SOC) will be targeted â itâs when. As cloud intrusions soared by 75% in the past year , and two in five enterprises suffered AI-related security breaches , every SOC leader needs to confront a brutal truth: Your defenses must either evolve as fast as the attackersâ tradecraft or risk being overrun by relentless, resourceful adversaries who pivot in seconds to succeed with a breach. Combining generative AI (gen AI), social engineering, interactive intrusion campaigns and an all-out assault on cloud vulnerabilities and identities, attackers are executing a playbook that seeks to capitalize on every SOC weakness they can find. CrowdStrikeâs 2024 Global Threat Report finds that nation-state attackers are taking identity-based and social engineering attacks to a new level of intensity. Nation-states have long used machine learning to craft phishing and social engineering campaigns. Now, the focus is on pirating authentication tools and systems including API keys and one-time passwords (OTPs). âWhat weâre seeing is that the threat actors have really been focused on...taking a legitimate identity. Logging in as a legitimate user. And then laying low, staying under the radar by living off the land by using legitimate tools,â Adam Meyers, senior vice president counter adversary operations at CrowdStrike, told VentureBeat during a recent briefing. Cybercrime gangs and nation-state cyberwar teams continue sharpening their tradecraft to launch AI-based attacks aimed at undermining the foundation of identity and access management (IAM) trust. By exploiting fake identities generated through deepfake voice, image and video data, these attacks aim to breach IAM systems and create chaos in a targeted organization. The Gartner figure below shows why SOC teams need to be prepared now for adversarial AI attacks, which most often take the form of fake identity attacks. Source: Gartner 2025 Planning Guide for Identity and Access Management. Published on October 14, 2024. Document ID: G00815708. Scoping the adversarial AI threat landscape going into 2025 âAs gen AI continues to evolve, so must the understanding of its implications for cybersecurity ,â Bob Grazioli, CIO and senior vice president of Ivanti , recently told VentureBeat. âUndoubtedly, gen AI equips cybersecurity professionals with powerful tools, but it also provides attackers with advanced capabilities. To counter this, new strategies are needed to prevent malicious AI from becoming a dominant threat. This report helps equip organizations with the insights needed to stay ahead of advanced threats and safeguard their digital assets effectively,â Grazioli said. A recent Gartner survey revealed that 73% of enterprises have hundreds or thousands of AI models deployed, while 41% reported AI-related security incidents. According to HiddenLayer , seven in 10 companies have experienced AI-related breaches, with 60% linked to insider threats and 27% involving external attacks targeting AI infrastructure. Nir Zuk, CTO of Palo Alto Networks , framed it starkly in an interview with VentureBeat earlier this year: Machine learning assumes adversaries are already inside, and this demands real-time responsiveness to stealthy attacks. Researchers at Carnegie Mellon University recently published â Current State of LLM Risks and AI Guardrails ,â a paper that explains the vulnerabilities of large language models (LLMs) in critical applications. It highlights risks such as bias, data poisoning and non-reproducibility. With security leaders and SOC teams increasingly collaborating on new model safety measures, the guidelines advocated by these researchers need to be part of SOC teamsâ training and ongoing development. These guidelines include deploying layered protection models that integrate retrieval-augmented generation (RAG) and situational awareness tools to counter adversarial exploitation. SOC teams also carry the support burden for new gen AI applications, including the rapidly growing use of agentic AI. Researchers from the University of California, Davis recently published â Security of AI Agents ,â a study examining the security challenges SOC teams face as AI agents execute real-world tasks. Threats including data integrity breaches and model pollution, where adversarial inputs may compromise the agentâs decisions and actions, are deconstructed and analyzed. To counter these risks, the researchers propose defenses such as having SOC teams initiate and manage sandboxing â limiting the agentâs operational scope â and encrypted workflows that protect sensitive interactions, creating a controlled environment to contain potential exploits. Why SOCs are targets of adversarial AI Dealing with alert fatigue, turnover of key staff, incomplete and inconsistent data on threats, and systems designed to protect perimeters and not identities, SOC teams are at a disadvantage against attackersâ growing AI arsenals. SOC leaders in financial services, insurance and manufacturing tell VentureBeat, under the condition of anonymity, that their companies are under siege, with a high number of high-risk alerts coming in every day. The techniques below focus on ways AI models can be compromised such that, once breached, they provide sensitive data and can be used to pivot to other systems and assets within the enterprise. Attackersâ tactics focus on establishing a foothold that leads to deeper network penetration. Reinforcing SOC defenses through AI model hardening and supply chain security SOC teams need to think holistically about how a seemingly isolated breach of AL/ML models could quickly escalate into an enterprise-wide cyberattack. SOC leaders need to take the initiative and identify which security and risk management frameworks are the most complementary to their companyâs business model. Great starting points are the NIST AI Risk Management Framework and the NIST AI Risk Management Framework and Playbook . VentureBeat is seeing that the following steps are delivering results by reinforcing defenses while also enhancing model reliability â two critical steps to securing a companyâs infrastructure against adversarial AI attacks: Commit to continually hardening model architectures. Deploy gatekeeper layers to filter out malicious prompts and tie models to verified data sources. Address potential weak points at the pretraining stage so your models withstand even the most advanced adversarial tactics. Never stop strengthing data integrity and provenance: Never assume all data is trustworthy. Validate its origins, quality and integrity through rigorous checks and adversarial input testing. By ensuring only clean, reliable data enters the pipeline, SOCs can do their part to maintain the accuracy and credibility of outputs. Integrate adversarial validation and red-teaming: Donât wait for attackers to find your blind spots. Continually pressure-test models against known and emerging threats. Use red teams to uncover hidden vulnerabilities, challenge assumptions and drive immediate remediation â ensuring defenses evolve in lockstep with attacker strategies. Enhance threat intelligence integration: SOC leaders need to support devops teams and help keep models in sync with current risks. SOC leaders need to provide devops teams with a steady stream of updated threat intelligence and simulate real-world attacker tactics using red-teaming. Increase and keep enforcing supply chain transparency: Identify and neutralize threats before they take root in codebases or pipelines. Regularly audit repositories, dependencies and CI/CD workflows. Treat every component as a potential risk, and use red-teaming to expose hidden gaps â fostering a secure, transparent supply chain. Employ privacy-preserving techniques and secure collaboration: Leverage techniques like federated learning and homomorphic encryption to let stakeholders contribute without revealing confidential information. This approach broadens AI expertise without increasing exposure. Implement session management, sandboxing, and zero trust starting with microsegmentation: Lock down access and movement across your network by segmenting sessions, isolating risky operations in sandboxed environments and strictly enforcing zero-trust principles. Under zero trust, no user, device or process is inherently trusted without verification. These measures curb lateral movement, containing threats at their point of origin. They safeguard system integrity, availability and confidentiality. In general, they have proven effective in stopping advanced adversarial AI attacks. Conclusion âCISO and CIO alignment will be critical in 2025,â Grazioli told VentureBeat. âExecutives need to consolidate resources â budgets, personnel, data and technology â to enhance an organizationâs security posture. A lack of data accessibility and visibility undermines AI investments. To address this, data silos between departments such as the CIO and CISO must be eliminated.â âIn the coming year, we will need to view AI as an employee rather than a tool,â Grazioli noted. âFor instance, prompt engineers must now anticipate the types of questions that would typically be asked of AI, highlighting how ingrained AI has become in everyday business activities. To ensure accuracy, AI will need to be trained and evaluated just like any other employee.â Stay in the know! Get the latest news in your inbox daily By subscribing, you agree to VentureBeat's Terms of Service. Thanks for subscribing. Check out more VB newsletters here . An error occured.Tamil Demand For Justice â Stumbling Block For NPP